Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.
Laurent LamHélène FontaineNathanael LapidusCéline DorivalJonathan BelletDominique LarreyPierre NahonAlpha DialloCarole CagnotClovis Luzivika NzingaFrançois TéouléGilles HejblumMarc BourlièreStanislas PolFabrice Carratnull nullPublished in: Pharmacoepidemiology and drug safety (2022)
DAAs were not associated with extrahepatic cancer development or reduction. They were associated with a decreased risk of PAD and an increased risk of ACD, supporting long-term cardiac monitoring after DAA therapy.